First new targeted therapy in more than a decade offers relief to patients with hives uncontrolled by antihistamines
First new targeted therapy in more than a decade offers relief to patients with hives uncontrolled by antihistamines
A landmark study from MHRA and University of Liverpool reveals the UK’s leadership in drug development and outlines …
In a shareholder letter released on 1 April 2025, MAIA Biotechnology revealed plans to advance telomere‐targeted therapies in …
The European regulatory body’s February 2025 meeting brings fresh treatment options for immunodeficiency and autoimmunity among other conditions, …
The FDA has approved Merilog (insulin-aspart-szjj), marking the first biosimilar to Novolog (insulin aspart), and widening affordable insulin …
With increasing geopolitical disruptions and shifting trial strategies, India emerges as an attractive destination for early-stage clinical trials, …
Grace Therapeutics reports that its Phase III STRIVE-ON trial showed GTx-104 significantly reduces clinically significant hypotension and improves …
Acadia Pharmaceuticals advances its serotonin 5-HT₂A inverse agonist, remlifanserin (ACP-204), into the final phases of clinical testing as …
On February 1, 2025, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s lebrikizumab, marking the first …
Vertex Pharmaceuticals earns approval for JOURNAVX™ (suzetrigine), a ground-breaking oral NaV1.8 pain channel inhibitor designed to target moderate-to-severe …
Already a subscriber? Log in